TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Companyâs lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTCRX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļTScan Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 2021
āļāļĩāļāļĩāđāļMacbeath (Gavin)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ194
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 16
āļāļĩāđāļāļĒāļđāđ830 Winter Street
āđāļĄāļ·āļāļWALTHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02451
āđāļāļĢāļĻāļąāļāļāđ18573999500
āđāļ§āđāļāđāļāļāđhttps://www.tscan.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTCRX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 2021
āļāļĩāļāļĩāđāļMacbeath (Gavin)
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Gavin Macbeath, Ph.D.
Dr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Director
Dr. Chrystal U. Louis
Chief Medical Officer
Ms. Katina Dorton, J.D.
Independent Director
Dr. Gabriela Gruia, M.D.
Independent Director
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. R. Keith Woods
Independent Director
Mr. Jason A. Amello
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
Dr. Gavin Macbeath, Ph.D.
Dr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Director
Dr. Chrystal U. Louis
Chief Medical Officer
Ms. Katina Dorton, J.D.
Independent Director